DFA

Showing 1 posts of 1 posts found.

Endogena’s retinitis pigmentosa treatment granted Orphan Drug Designation by FDA

May 12, 2021
Research and Development DFA, Endogena, Orphan Drug Designation

Endogena Therapeutics Inc has been granted Orphan Drug Designation for its EA-2353 ophthalmic suspension targeting retinitis pigmentosa by the FDA. …

The Gateway to Local Adoption Series

Latest content